Publicaciones en colaboración con investigadores/as de National and Kapodistrian University of Athens (11)

2024

  1. Attributable mortality of infections caused by carbapenem-resistant Enterobacterales: results from a prospective, multinational case-control-control matched cohorts study (EURECA)

    Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases, Vol. 30, Núm. 2, pp. 223-230

2023

  1. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

2017

  1. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study

    The Lancet Infectious Diseases, Vol. 17, Núm. 7, pp. 726-734

  2. Geographical variation in therapy for bloodstream infections due to multidrug-resistant Enterobacteriaceae: a post-hoc analysis of the INCREMENT study

    International Journal of Antimicrobial Agents, Vol. 50, Núm. 5, pp. 664-672

2016

  1. A Predictive Model of Mortality in Patients With Bloodstream Infections due to Carbapenemase-Producing Enterobacteriaceae

    Mayo Clinic Proceedings, Vol. 91, Núm. 10, pp. 1362-1371

  2. A multinational, preregistered cohort study of β-lactam/β-lactamase inhibitor combinations for treatment of bloodstream infections due to extended-spectrum-β-lactamase-producing enterobacteriaceae

    Antimicrobial Agents and Chemotherapy, Vol. 60, Núm. 7, pp. 4159-4169

  3. Ertapenem for the treatment of bloodstream infections due to ESBL-producing Enterobacteriaceae: A multinational pre-registered cohort study

    Journal of Antimicrobial Chemotherapy, Vol. 71, Núm. 6, pp. 1672-1680

2010

  1. Acquired carbapenemases in Gram-negative bacterial pathogens: Detection and surveillance issues

    Clinical Microbiology and Infection, Vol. 16, Núm. 2, pp. 112-122

2007

  1. Metallo-β-lactamases as emerging resistance determinants in Gram-negative pathogens: open issues

    International Journal of Antimicrobial Agents

2004

  1. Twelve years of fluconazole in clinical practice: Global-trends in species distribution and fluconazole susceptibility of bloodstream isolates of Candida

    Clinical Microbiology and Infection, Vol. 10, Núm. SUPPL. 1, pp. 11-23

2001

  1. Variations in the prevalence of strains expressing an extended-spectrum β-lactamase phenotype and characterization of isolates from Europe, the Americas, and the Western Pacific region

    Clinical Infectious Diseases, Vol. 32, Núm. 10, pp. S94-S103